• 1
    Jones EA, Bergasa NV. The pruritus of cholestasis. HEPATOLOGY 1999; 29: 1003-1006.
  • 2
    Bergasa NV. The pruritus of cholestasis. J Hepatol 2005; 43: 1078-1088.
  • 3
    Magerl W. Neural mechanisms of itch sensation. IASP Newsletter 1996;Sept-Oct.
  • 4
    Gustafsson H, Flood K, Berge OG, Brodin E, Olgart L, Stiller CO. Gabapentin reverses mechanical allodynia induced by sciatic nerve ischemia and formalin-induced nociception in mice. Exp Neurol 2003; 182: 427-434.
  • 5
    Rodrigues-Filho R, Campos MM, Ferreira J, Santos AR, Bertelli JA, Calixto JB. Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain. Brain Res 2004; 1018(2): 159-170.
  • 6
    Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999; 13: 227-228.
  • 7
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23: 56-62.
  • 8
    Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 1992; 49: 630-636.
  • 9
    Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549.
  • 10
    Bergasa NV, Talbot TL, Schmitt JP, Alling DW, Swain MG, Turner M, et al. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. HEPATOLOGY 1998; 27: 679-684.
  • 11
    Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Schmitt JM, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Ann Intern Med 1995; 123: 161-167.
  • 12
    Bergasa NV, Alling DW, Talbot TL, Wells M, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-434.
  • 13
    Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991; 25: 400-403.
  • 14
    Little R, Rubin D. Statistical Analysis with Missing Data. 2nd ed. New York: Wiley Interscience, 2002.
  • 15
    McGee M, Bergasa NV. Imputing Missing Data in Clinical Pilot Studies. Technical Report. Dallas, TX: Southern Methodist University, 2005.
  • 16
    Kradin RL. The placebo response: its putative role as a functional salutogenic mechanism of the central nervous system. Perspect Biol Med 2004; 47: 328-338.
  • 17
    de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166.
  • 18
    Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91: 1022-1023.
  • 19
    Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-1269.
  • 20
    Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001; 13: 1393-1394.
  • 21
    Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-722.
  • 22
    Horta ML, Ramos L, Goncalves ZR. The inhibition of epidural morphine-induced pruritus by epidural droperidol. Anesth Analg 2000; 90: 638-641.
  • 23
    Horta ML, Ramos L, Goncalves Zda R, de Oliveira MA, Tonellotto D, Teixeira JP, et al. Inhibition of epidural morphine-induced pruritus by intravenous droperidol. The effect of increasing the doses of morphine and of droperidol. Reg Anesth 1996; 21: 312-317.
  • 24
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: MolinoffPB, RuddonRW, eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: 399-430.
  • 25
    Coté L, Crutcher M. The basal ganglia. In: KandelER, ScwartzJH, JessellTM, eds. Principles of Neural Science. Norwalk: Appleton and Lange, 1991: 647-659.
  • 26
    McFarland NR, Haber SN. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 2002; 22: 8117-8132.
  • 27
    Hsieh JC, Hagermark O, Stahle-Backdahl M, Ericson K, Eriksson L, Stone-Elander S, et al. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994; 72: 3004-3008.
  • 28
    Drzezga A, Darsow U, Treede RD, Siebner H, Frisch M, Munz F, et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001; 92(1-2): 295-305.
  • 29
    Mochizuki H, Tashiro M, Kano M, Sakurada Y, Itoh M, Yanai K. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003; 105(1-2): 339-346.
  • 30
    Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol 1983; 94: 341-344.
  • 31
    Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl) 2001; 157: 381-387.
  • 32
    Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004; 303: 1162-1167.
  • 33
    Elias E. Liver Transplantation. J Roy Coll Phys London 1993; 27: 224-232.
  • 34
    Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002; 95: 547-552.